Drug Trial Radar · NCT01265498
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
Last checked: Nov 20, 2026Latest source record: Apr 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
283
Actual
Start
Mar 2011
Primary completion
Jan 2014
Study completion Sep 2014
Sponsor
- Sponsor type
- NIH
- First posted
- Dec 23, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Administration of the farnesoid X receptor (FXR) ligand obeticholic acid (OCA) for 72 weeks to subjects with biopsy evidence of nonalcoholic steatohepatitis (NASH) will result in improvement in their liver disease as measured by changes in the nonalcoholic fatty liver disease (NAFLD) activity score (NAS).
Conditions
- Nonalcoholic Fatty Liver Disease (NAFLD)
- Nonalcoholic Steatohepatitis (NASH)
Interventions
obeticholic acidDrug
25 mg daily for 72 weeks
placeboDrug
placebo capsule, 25 mg daily for 72 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hepatic Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS)Time frame: baseline to 72 weeks
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of California, San Diego
San Diego, California
University of California, San Francisco
San Francisco, California
Indiana University
Indianapolis, Indiana
St. Louis University
St Louis, Missouri
Duke University Medical Center
Durham, North Carolina
Case Western Reserve University
Cleveland, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio
Virginia Commonwealth University
Richmond, Virginia
Virginia Mason Medical Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.